RNAZ · Transcode Therapeutics, Inc. · Analyst Estimates
$1.73
-0.03 (-1.70%)
At close · Oct 6
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Due to the Company's recurring and expected continuing losses from operations, the Company has concluded there is substantial doubt concerning its ability to continue as a going concern for one year after the issuance of these consolidated financial statements without additional capital becoming available.”View the 10-Q filed Aug 14, 2026
Market Cap
$28.61M
Shares
16.93M
Volume · Oct 6
33.01K
Avg daily vol (3M)
51.68K
Analyst Estimates
Compare analyst forecasts for Transcode Therapeutics, Inc. across metrics and forecast periods.
Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.
Compiled consensus
These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.
Captured 2026-09-18 03:00 UTC · Publication dates shown per estimate · 4 metric / period groups
FY ending 2025-12-31
| Metric | Low | Average | High | Analyst count |
|---|---|---|---|---|
|
Revenue
Publication date not stated |
0
|
0
|
0
|
— |
|
Revenue
analysts
Publication date not stated |
— | — | — |
0
|
Q ending 2025-03-31
| Metric | Low | Average | High | Analyst count |
|---|---|---|---|---|
|
Revenue
Publication date not stated |
0
|
0
|
0
|
— |
|
Revenue
analysts
Publication date not stated |
— | — | — |
0
|